Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer

Noel T. Brewer,Jessica T. DeFrank,Wing K. Chiu,Joseph G. Ibrahim,Christine M. Walko,Peter Rubin,Oludamilola Olajide,Susan G. Moore,Rachael E. Raab,Daniel R. Carrizosa,Steven W. Corso,Garry Schwartz,Jeffrey Peppercorn,Howard L. McLeod,Lisa A. Carey,William J. Irvin

Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer

2014

Noel T. Brewer
Jessica T. DeFrank
Wing K. Chiu
Joseph G. Ibrahim
Christine M. Walko
Peter Rubin
Oludamilola Olajide
Susan G. Moore
Rachael E. Raab
Daniel R. Carrizosa
Steven W. Corso
Garry Schwartz
Jeffrey Peppercorn
Howard L. McLeod
Lisa A. Carey
William J. Irvin

Background: CYP2D6 is a critical enzyme in the metabolism of tamoxifen and potentially a key determinant in breast cancer outcomes. Our study examined patients' b

Keywords:

Breast cancer
Pharmacogenomics
Gynecology
Pharmacogenetics
Tamoxifen
Genotype
Tamoxifen therapy
CYP2D6
Medicine
risk communication

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations